LZ Therapeutics Wednesday, June 30th, 2010
LZ Therapeutics develops therapeutics for patients at different stages of Parkinson’s disease. It offers neuroprotective/neurorestoritive therapies for early-stage Parkinson’s disease (PD); a combination therapy with levodopa-enhancing and anti-dyskinesia effects designed for mid-stage PD patients; and gene therapies for advanced PD patients. Lazarus will conduct pre-clinical testing of its drug in preparation for an Investigational New Drug filing